3 Houston innovators to know this week

who's who

This week's innovators to know includes Kenneth Liao of Baylor St. Luke's, Serafina Lalany of Houston Exponential, and Nick Cardwell of McCord. Photos courtesy

Editor's note: In today's Monday roundup of Houston innovators, I'm introducing you to three innovators across industries — from robotics in health care to smart city technology — all making headlines in Houston this week.

Kenneth Liao, chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke's Medical Center,

Houston cardiac surgeon outpaces much of the country in game-changing robotics

Dr. Kenneth Liao, chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke's Medical Center, is one of around 50 surgeons in the country considered experts of this new surgery robotics tool. Photo courtesy of Baylor St. Luke's

Dr. Kenneth Liao is the only cardiatric surgeon in Houston — and one of only around 50 in the world — who uses a specific robot to conduct heart surgeries. The robot, known as the da Vinci, was first designed to assist in battlefield procedures.

Now on its fourth generation, the robot allows surgeons like Liao to treat heart diseases and conditions that typically would require open heart surgery through a one-to-two inch incision near the ribs. In many surgeries, it also allows surgeons to keep a patient's heart beating, lowering the risk of stroke.

"It's a totally game changing component to conventional surgery," Liao says. Read more.

Serafina Lalany, chief of staff at Houston Exponential 

Serafina Lalany joins the Houston Innovators Podcast to discuss the Listies. Photo courtesy of Serafina Lalany

Houston tech companies deserve a shoutout, and, after mulling it over for quite a while, Serafina Lalany and her team at Houston Exponential are making it happen with The Listies, a new awards program.

"The idea for The Listies has been in the back of our minds for a long time," says Lalany, chief of staff at HX, on this week's episode of the Houston Innovators Podcast. "There has always been a need in the ecosystem to celebrate the wins and vibrant culture we have here. This is an opportunity to pay homage to that."

The nomination deadline has been extended for the awards. Nominate a worthy startup, person, investor or corporate by Friday, November 6. Click here to submit. And, click here to stream the episode and read more.

Nick Cardwell, vice president of digital innovation at McCord

A new executive hire for McCord is going to focus on bringing smart city technology to Generation Park. Rendering courtesy of McCord

At 4,200 acres, the Generation Park master-planned development is evolving into its own ecosystem of sorts — one that has a huge opportunity for tech and smart city initiatives. Houston-based real estate developer, McCord, has hired Nick Cardwell as vice president of digital innovation. In the newly created role, Cardwell will be tasked with bringing data-driven solutions, digital transformation, and other smart city innovation to Generation Park.

"McCord's vision for Generation Park is the future of commercial development, pushing digital innovation into the forefront and leveraging cutting-edge technologies throughout their portfolio. I am beyond thrilled to join the McCord team and help make that vision a reality," says Cardwell, in the release. "Through the use of experiences, data, and collaborations, we will accelerate learnings and, in turn, advance resources that will truly improve people's lives." Read more.

Dr. Kenneth Liao, chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke's Medical Center, is one of around 50 surgeons in the country considered experts of this new surgery robotics tool. Photo courtesy of Baylor St. Luke's

Houston cardiac surgeon outpaces much of the country in game-changing robotics

matters of the heart

Dr. Kenneth Liao is pioneering a less invasive form of heart surgery at a time when distanced medicine has become more important than ever with the help of six team members and one robot.

As the chief of cardiothoracic transplantation and mechanical circulatory support at Baylor St. Luke's Medical Center, Liao has performed 116 robotic cardiac surgeries since coming on board in 2019 (as of press time). With Liao at the helm, Baylor St. Luke's has become a top cardiac robotics program in the country and is the only hospital in Houston to practice this highly-specialized form of surgery.

Liao's four-armed robot friend is known as the da Vinci robotic system and was first designed to assist in battlefield procedures. Now on its fourth generation, the robot allows surgeons like Liao to treat heart diseases and conditions that typically would require open heart surgery through a one-to-two inch incision near the ribs. In many surgeries, it also allows surgeons to keep a patient's heart beating, lowering the risk of stroke.

"It's a totally game changing component to conventional surgery," Liao says, who's one of about 50 surgeons in the country with his level of command over the tool.

Once inside, the da Vinci robot uses tiny instruments to perform surgical practices from suturing to cutting to tying a knot all within the rigid chest cage, which in a typical open heart surgery would have to be broken to perform such tasks.

The surgeon, who's seated about 10 feet away from the patient, controls the tools through a joystick connected to a computer console that shows an enhanced 3D view of the patient's chest. Liao says the screen provides a better visual of the heart than if he was seeing it with his own eyes, as it magnifies the field of surgery tenfold. This method also gives surgeons a better view of areas of the heart that they cannot easily see from above during traditional procedures.

The da Vinci can be used for bypass, grafting, pacemaker, and valve repair surgeries, and it has been proven to result in less blood loss and a faster, less painful recovery. Similar technology has also been adopted for prostate and gynecological surgeries. "It gives you the advantage of minimizing the trauma," Liao says.

And though the da Vinci was developed years before the pandemic, it puts patients at a lower risk of exposure to any outside contaminants, Liao adds, as the robot alone is interfacing with the patient through a small port, compared to doctors, nurses, and assistants hovering over an open chest cavity.

"Technology will theoretically reduce a patient's exposure to COVID in the operation room," he says. "I think that's common sense."

Liao was an early adopter of robotics, when the technology was much less user friendly. He performed the first robotic heart surgery in the state of Minnesota in 2003 and has worked with the developers of the da Vinci ever since to help improve the product after many other surgeons dismissed it.

He says today there is a renewed interest in the highly technical process and he believes it will become an emphasis for younger surgeons.

"This generation of surgeons are young and they are very indebted to computer technology and games. For them looking at screens and controlling the hand joystick control is much more familiar than for the older generation that was trained 20 years ago." he says.

The incredible technology helps, too. "A lot of times, as surgeons, we train in the old way. It's very difficult to change the systems," he says. "You need a major technology revolution to change the teaching and training."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines forms partnership with Italian companies for lunar exploration services

to the moon

Houston-based space technology, infrastructure and services company Intuitive Machines has forged a partnership with two Italian companies to offer infrastructure, communication and navigation services for exploration of the moon.

Intuitive Machines’ agreement with the two companies, Leonardo and Telespazio, paves the way for collaboration on satellite services for NASA, a customer of Intuitive Machines, and the European Space Agency, a customer of Leonardo and Telespazio. Leonardo, an aerospace, defense and security company, is the majority owner of Telespazio, a provider of satellite technology and services.

“Resilient, secure, and scalable space infrastructure and space data networks are vital to customers who want to push farther on the lunar surface and beyond to Mars,” Steve Altemus, co-founder and CEO of Intuitive Machine, said in a news release.

Massimo Claudio Comparini, managing director of Leonardo’s space division, added that the partnership with Intuitive Machines is a big step toward enabling human and robotic missions from the U.S., Europe and other places “to access a robust communications network and high-precision navigation services while operating in the lunar environment.”

Intuitive Machines recently expanded its Houston Spaceport facilities to ramp up in-house production of satellites. The company’s first satellite will launch with its upcoming IM‑3 lunar mission.

Intuitive Machines says it ultimately wants to establish a “center of space excellence” at Houston Spaceport to support missions to the moon, Mars and the region between Earth and the moon.

Houston hospitals win $50M grant for ibogaine addiction treatment research

ibogaine funding

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Tesla no longer world's biggest EV maker as sales fall for second year

Tesla Talk

Tesla lost its crown as the world’s bestselling electric vehicle maker as a customer revolt over Elon Musk’s right-wing politics, expiring U.S. tax breaks for buyers and stiff overseas competition pushed sales down for a second year in a row.

Tesla said that it delivered 1.64 million vehicles in 2025, down 9% from a year earlier.

Chinese rival BYD, which sold 2.26 million vehicles last year, is now the biggest EV maker.

It's a stunning reversal for a car company whose rise once seemed unstoppable as it overtook traditional automakers with far more resources and helped make Musk the world's richest man. The sales drop came despite President Donald Trump's marketing effort early last year when he called a press conference to praise Musk as a “patriot” in front of Teslas lined up on the White House driveway, then announced he would be buying one, bucking presidential precedent to not endorse private company products.

For the fourth quarter, Tesla sales totaled 418,227, falling short of even the much reduced 440,000 target that analysts recently polled by FactSet had expected. Sales were hit hard by the expiration of a $7,500 tax credit for electric vehicle purchases that was phased out by the Trump administration at the end of September.

Tesla stock fell 2.6% to $438.07 on Friday.

Even with multiple issues buffeting the company, investors are betting that Tesla CEO Musk can deliver on his ambitions to make Tesla a leader in robotaxi services and get consumers to embrace humanoid robots that can perform basic tasks in homes and offices. Reflecting that optimism, the stock finished 2025 with a gain of approximately 11%.

The latest quarter was the first with sales of stripped-down versions of the Model Y and Model 3 that Musk unveiled in early October as part of an effort to revive sales. The new Model Y costs just under $40,000 while customers can buy the cheaper Model 3 for under $37,000. Those versions are expected to help Tesla compete with Chinese models in Europe and Asia.

For fourth-quarter earnings coming out in late January, analysts are expecting the company to post a 3% drop in sales and a nearly 40% drop in earnings per share, according to FactSet. Analysts expect the downward trend in sales and profits to eventually reverse itself as 2026 rolls along.

Musk said earlier last year that a “major rebound” in sales was underway, but investors were unruffled when that didn't pan out, choosing instead to focus on Musk's pivot to different parts of business. He has has been saying the future of the company lies with its driverless robotaxis service, its energy storage business and building robots for the home and factory — and much less with car sales.

Tesla started rolling out its robotaxi service in Austin in June, first with safety monitors in the cars to take over in case of trouble, then testing without them. The company hopes to roll out the service in several cities this year.

To do that successfully, it needs to take on rival Waymo, which has been operating autonomous taxis for years and has far more customers. It also will also have to contend with regulatory challenges. The company is under several federal safety investigations and other probes. In California, Tesla is at risk of temporarily losing its license to sell cars in the state after a judge there ruled it had misled customers about their safety.

“Regulatory is going to be a big issue,” said Wedbush Securities analyst Dan Ives, a well-known bull on the stock. “We're dealing with people's lives.”

Still, Ives said he expects Tesla's autonomous offerings will soon overcome any setbacks.

Musk has said he hopes software updates to his cars will enable hundreds of thousands of Tesla vehicles to operate autonomously with zero human intervention by the end of this year. The company is also planning to begin production of its AI-powered Cybercab with no steering wheel or pedals in 2026.

To keep Musk focused on the company, Tesla’s directors awarded Musk a potentially enormous new pay package that shareholders backed at the annual meeting in November.

Musk scored another huge windfall two weeks ago when the Delaware Supreme Court reversed a decision that deprived him of a $55 billion pay package that Tesla doled out in 2018.

Musk could become the world's first trillionaire later this year when he sells shares of his rocket company SpaceX to the public for the first time in what analysts expect would be a blockbuster initial public offering.

View All Listings